Aurora Cannabis: Medical Sales Boom Worldwide, Cash Flow to Swing Positive – Quarterly Update Report

Download the Complete Report Here

By Brandon Hornback

Aurora Cannabis Inc. (NASDAQ: ACB) smoked different quarter, led by top-line growth, profitability, and disciplined superior allocation. And successful caller news, there’s affirmative currency travel close astir the corner.

Take a deed disconnected this: The apical enactment accrued 11%, driven chiefly by beardown aesculapian cannabis show linked to precocious request from Germany, Poland, and Australia. Gross borderline expanded importantly to 61%, led by the aesculapian business, which continues to outperform the broader cannabis industry.

Management expects a instrumentality to affirmative escaped currency travel successful its fiscal 3rd quarter, which ends successful December. Additionally, ACB maintains a rock-solid equilibrium expanse with C$142 cardinal successful cash, and nary cannabis-related debt.

To apical it off, the re-certification of Aurora’s EU-GMP and Leuna installation enlargement has placed Aurora among a abbreviated database of cannabis companies, offering visibility for sustainable maturation and borderline improvement.

Turning to valuation, ACB is trading astatine 0.9x guardant income and 6.5x EV/EBITDA, beneath adjacent averages adjacent amid an charismatic manufacture positioning. For investors funny successful a straightforward play connected aesculapian and planetary cannabis markets, ACB is simply a sanction to support connected the shelf.

Download the afloat study to larn much astir Aurora’s translation from turnaround communicative to trailblazer.

Download the Complete Report Here

Read Exec Edge’s Initiation connected Aurora Here

Subscribe to our Weekly Newsletter to Receive All Research

Contact:

Executives-Edge.com

[email protected]